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Background: The CHADS2 scoring system is simple and widely accepted for predicting thromboembolism
in patients with nonvalvular atrial ﬁbrillation (NVAF). Although congestive heart failure (CHF) is a
component of the CHADS2 score, the deﬁnition of CHF remains unclear. We previously reported that the
presence of CHF was a strong predictor of left atrial appendage (LAA) thrombus. Therefore, the present
study aimed to elucidate the relationship between LAA thrombus and the brain natriuretic peptide (BNP)
level in patients with unanticoagulated NVAF.
Methods: The study included 524 consecutive patients with NVAF who had undergone transesophageal
echocardiography to detect intracardiac thrombus before cardioversion between January 2006 and
December 2008, at Hiroshima City Asa Hospital. The exclusion criteria were as follows: paroxysmal atrial
ﬁbrillation, unknown BNP levels, prothrombin time international normalized ratio Z2.0, and hospita-
lization for systemic thromboembolism.
Results: Receiver operating characteristic analysis yielded optimal plasma BNP cut-off levels of 157.1
pg/mL (area under the curve, 0.91; po0.01) and 251.2 pg/mL (area under the curve, 0.70; po0.01) for
identifying CHF and detecting LAA thrombus, respectively. Multivariate analyses demonstrated that a
BNP level 4251.2 pg/mL was an independent predictor of LAA thrombus (odds ratio, 3.51; 95%
conﬁdence interval, 1.08–10.7; p¼0.046).
Conclusions: In patients with unanticoagulated NVAF, a BNP level 4251.2 pg/mLmay be helpful for predicting
the incidence of LAA thrombus and may be used as a surrogate marker of CHF. The BNP level is clinically useful
for the risk stratiﬁcation of systemic thromboembolism in patients with unanticoagulated NVAF.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Systemic thromboembolism, including ischemic stroke and
transient ischemic attack, is a serious complication in patients
with atrial ﬁbrillation (AF). Several randomized prospective trials
investigating nonvalvular atrial ﬁbrillation (NVAF) have conﬁrmed
that warfarin administration signiﬁcantly reduces the risk of
stroke, thereby providing a basis for guidelines promoting the
use of warfarin in patients with NVAF [1,2]. The congestive heart
failure (CHF), hypertension, age, diabetes mellitus, and prior stroke
(CHADS2) scoring system is easy for physicians to remember and
apply. Additionally, it has been widely validated for risk stratiﬁca-
tion to predict stroke in patients with NVAF [3]. The CHADS2 score
assigns 1 point each for CHF, hypertension, age Z75 years, and
diabetes mellitus, and 2 points each for prior stroke or transient
ischemic attack. Current guidelines recommend anticoagulant
therapy for patients with a CHADS2 score Z2, because the risk
of ischemic stroke outweighs the risk of bleeding with antic-
oagulant therapy [4–6].
Most thrombi associated with NVAF originate in the left atrial
appendage (LAA) [7–9]. We previously reported that the serum d-
dimer level is clinically useful for guiding the management of
patients. In addition, the presence of CHF, a history of embolic
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events, and the serum d-dimer level are signiﬁcant predictors of
LAA thrombus [10].
Various studies consider CHF as involving the following factors:
acute pulmonary edema [3], low ejection fraction (EF) [2,11], New
York Heart Association (NYHA) functional classiﬁcation Z II [10],
and a history of hospitalization for CHF [2,11]. However, the
abovementioned clinical criteria are qualitative; therefore, the
quantitative deﬁnition of CHF remains unclear. Brain natriuretic
peptide (BNP) is widely used as a clinical index of the severity of
CHF [12]. Therefore, the present study aimed to elucidate the
relationship between LAA thrombus and the BNP level and to
determine if the BNP level is a quantitative marker of CHF in
patients with unanticoagulated NVAF.
2. Material and methods
2.1. Study population
A total of 524 consecutive patients with NVAF who had
undergone transesophageal echocardiography (TEE) to detect
intracardiac thrombus before cardioversion between January
2006 and December 2008, at Hiroshima City Asa Hospital were
enrolled. The study was approved by the Institutional Review
Board of Hiroshima City Asa Hospital, and the patients provided
consent for inclusion in the study.
Plasma BNP and d-dimer levels were measured simultaneously
at the time of TEE. The exclusion criteria were as follows: pro-
thrombin time international normalized ratio (PT-INR) Z2.0 as a
gold standard of warfarin control, paroxysmal AF, organic valvular
heart disease, presence of prosthetic valve, and hospitalization due
to acute myocardial infarction or systemic thromboembolism,
including ischemic stroke and transient ischemic attack. Patients
with paroxysmal AF were excluded because its onset could not be
determined and its impact on the BNP level was not known.
2.2. Deﬁnition of NVAF
According to the guidelines of AF published by the American
College of Cardiology, the American Heart Association, and the
European Society of Cardiology [13], patients with persistent or
permanent AF were included.
2.3. BNP level measurement
All assays were performed at our institution, and all investigators
and laboratory personnel were blinded to the clinical status of each
patient. Plasma samples for BNP analysis were collected in chilled
disposable tubes containing aprotinin (500 kallikrein IU/mL), imme-
diately placed on ice, and centrifuged at 4 1C. Plasma was frozen,
aliquoted, and stored at 30 1C until analyzed for the BNP level using
a speciﬁc immunoradiometric assay for human BNP (Shionogi Co., Ltd.,
Osaka, Japan).
2.4. TEE examination
TEE was performed using commercially available equipment with
a multiplane phase array transducer. Prior to TEE, all participants
received a detailed explanation of the procedure and provided written
informed consent. A total of 204 patients with AF rhythm underwent
TEE. For local anesthesia, lidocaine hydrochloride was administered at
the throat for 5 min accompanied by lidocaine hydrochloride spray to
anesthetize the posterior pharynx and tongue. The maximum LAA
area was measured by tracing a line along the entire endocardial LAA
border. The minimal LAA emptying peak ﬂow velocity was measured
with a sample volume placed at the entrance of the LAA.
2.5. Identiﬁcation of LAA thrombus
A thrombus was deﬁned as a circumscribed and uniformly
echo-dense intracavitary mass that was distinct from the under-
lying left atrium or LAA endocardium, and the pectinate muscles
in more than 1 imaging plane. Echocardiography technicians were
blinded to the plasma BNP level. All TEE data were analyzed
independently by 2 cardiologists, and interobserver differences
were resolved by a third cardiologist.
2.6. Statistical analysis
Continuous variables were compared using the Mann–Whitney
U-test, and categorical variables were compared using the chi-
square or Fisher's exact test where appropriate. Continuous vari-
ables are expressed as median (interquartile range), and catego-
rical variables as numbers and percentages. The optimal cut-off
level of BNP for predicting LAA thrombus was calculated by using
receiver operating characteristic (ROC) curve analysis. The Person
product-moment correlation coefﬁcient was used to evaluate the
associations of the plasma BNP level with the plasma D-dimer
level and LAA velocity.
Univariate logistic regression analysis was used to determine
the associations of clinical and laboratory variables with the
presence of LAA thrombus. Furthermore, multivariate logistic
regression analysis adjusted for BNP, CHF, and EF was performed
to identify independent clinical predictors of LAA thrombus. CHF
(i.e., NYHA classiﬁcation Z II) was considered as the gold standard
for the multivariate analysis. The level of signiﬁcance for all
analyses was set at po0.05. All analyses were performed using
JMPs Statistical Analysis Software (version 8.0.1J, SAS Institute,
Cary, NC, USA).
3. Results
3.1. Clinical characteristics of the study population
Among the 524 consecutive patients examined using TEE
between 2006 and 2012, 204 were included in the study. The
study ﬂowchart is presented in Fig. 1. The median age of the
patients was 69 years (interquartile range, 63–75 years), and 58
(28.4%) were women. Moreover, 143 patients (70.1%) had hyper-
tension, 132 (64.7%) had CHF (NYHA classiﬁcation Z II), 51 (25.0%)
had diabetes mellitus, and 30 (25.0%) had thromboembolism. The
prevalence of warfarin treatment was 20.6%.
Fig. 1. Flowchart depicting the inclusion of patients in this study. NVAF, non-
valvular atrial ﬁbrillation; INR, international normalized ratio.
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3.2. Prevalence of LAA thrombus
The clinical characteristics of patients with and those without
LAA thrombus are presented in Table 1. LAA thrombi were detected
in 30 (14.7%) patients with NVAF. Patients with LAA thrombus had
a higher frequency of CHF (NYHA classiﬁcation Z II) and higher
plasma BNP and D-dimer levels compared to those in patients
without LAA thrombus. In contrast, patients with LAA thrombus
had lower EF and LAA velocities compared to those in patients
without LAA thrombus. The sensitivities of NYHA classiﬁcations
Z II and Z III for predicting LAA thrombus were 83.3% and 63.3%,
respectively. The distributions of CHADS2 scores in patients with
and those without LAA thrombus are presented in Fig. 2.
3.3. Associations of the BNP level with the D-dimer level and LAA
velocity
We investigated the associations of the plasma BNP level with
the plasma D-dimer level and LAA velocity. The BNP level was
positively associated with the D-dimer level (po0.01, R2¼0.14)
and negatively associated with peak LAA velocity (p¼0.028,
R2¼0.25) (Fig. 3).
3.4. Diagnostic accuracy of the BNP level for predicting LAA
thrombus
The optimal plasma cut-off level of BNP for detecting LAA
thrombus was 251.2 pg/mL (AUC, 0.70; po0.01; sensitivity, 73.3%;
speciﬁcity, 69.2%) (Fig. 4). For this cut-off, the negative predictive
value was 93% and the positive likelihood ratio was 1.88. Patients
with high plasma BNP levels (i.e., 4251.2 pg/mL) had higher
median plasma D-dimer levels compared to those in patients with
low plasma BNP levels (1.40 μg/mL; interquartile range,
0.68–3.02 μg/mL vs. 0.60 μg/mL; interquartile range, 0.50–1.1 μg/
mL; po0.01).
3.5. Predictors of the presence of LAA thrombus
Univariate analysis identiﬁed a BNP level 4251.2 pg/mL, CHF
(NYHA classiﬁcation ZII), and EF o40.2% (ROC analysis yielded an
optimal EF cut-off value of 40.2% for identifying LAA thrombus).
Therefore, these variables were entered into the multivariate model.
Themultivariate analysis demonstrated that a BNP level 4251.2 pg/mL
was a signiﬁcant independent predictor of LAA thrombus (odds ratio,
3.15; 95% conﬁdence interval, 1.08–10.7) (Table 2).
4. Discussion
The present study found that the plasma BNP level was higher
in patients with LAA thrombus than in those without LAA
thrombus. Additionally, the BNP level was negatively associated
with peak LAA velocity evaluated using TEE and positively asso-
ciated with the D-dimer level. Moreover, the optimal plasma cut-
off level of BNP for detecting LAA was 251.2 pg/mL, and a plasma
BNP level 4251.2 pg/mL was an independent predictor of LAA
thrombus in patients with unanticoagulated NVAF. Therefore, a
plasma BNP level 4251.2 pg/mL could be used to differentiate
between patients with and those without LAA thrombus.
Patients with NVAF are treated with anticoagulation therapy on
the basis of the CHADS2 scoring system because this system is
convenient and easy to apply for predicting thromboembolism in
these patients. However, for the management of AF, the deﬁnition
of CHF is unclear in the current guidelines [14,15].
The BNP level is widely used for assessing patients with CHF.
An elevated BNP level is correlated with left ventricular systolic
and diastolic dysfunction [12,16,17]. Previous studies have demon-
strated that the BNP level is associated with left ventricular ﬁlling
pressure [18,19] and is well correlated with the severity of heart
failure [20,21]. Recent clinical reports have shown that blood
coagulability is enhanced in patients with AF [22,23]. Jafri et al.
[24] reported that patients with severe heart failure with a high
norepinephrine level or low EF are more likely to have an acti-
vated platelet and coagulation system. In addition to hemostatic
Table 1
Baseline characteristics of patients with and those without left atrial appendage thrombus.
Characteristic LAA thrombus () (n¼174) LAA thrombus (þ) (n¼30) p-Value
Age, years 69 (63–75) 72 (66–77) 0.15
Male sex, n (%) 124 (71.3%) 22 (73.3%) 0.82
Hypertension, n (%) 123 (70.7%) 20 (66.7%) 0.66
Diabetes mellitus, n (%) 45 (25.9%) 6 (20.0%) 0.48
Dyslipidemia, n (%) 84 (48.3%) 11 (36.7%) 0.24
CHF, n (%) 107 (61.5%) 25 (83.3%) 0.015
NYHA, n (%) 0.027
I 67 (38.5%) 5 (16.7%)
II 44 (25.3%) 6 (20%)
III 52 (29.9%) 17 (56.7%)
IV 11 (6.3%) 2 (6.7%)
History of admission for CHF, n (%) 18 (10.3%) 3 (10.0%) 0.95
History of thromboembolism, n (%) 23 (13.2%) 7 (23.3%) 0.17
eGFR (mL/min/1.73 m²) 66.2 (55.8–77.7) 55.5 (39.3–59.7) o0.01
BNP (pg/mL) 200.3 (118.2–387.7) 458.9 (216.5–677.8) o0.01
BNP 4251.2 pg/mL, n (%) 68 (39.1%) 22 (73.3%) o0.01
CHADS2 2.1 (1.9–2.3) 2.6 (2.1–3.1) 0.047
D-dimer (mg/mL) 0.70 (0.50–1.50) 1.80 (1.05–3.45) o0.01
BMI (kg/m²) 23.8 (21.8–26.8) 23.6 (20.2–25.4) 0.25
EF (%) 53.5 (43.0–60.0) 44.3 (32.6–57.5) 0.022
LAA area (cm²) 6.1 (4.7–7.8) 6.0 (5.0–9.0) 0.27
LAA velocity (cm/s) 29.4 (21.4–43.1) 22.3 (11.2–27.0) o0.01
INR at the time of TEE 1.02 (0.99–1.15) 1.07 (1.01–1.22) 0.08
Warfarin treatment, n (%) 38 (21.8%) 4 (13.3%) 0.27
CHF, congestive heart failure; NYHA, New York Heart Association; eGFR, estimated glomerular ﬁltration rate; BNP, brain natriuretic peptide; BMI, body mass index;
EF, ejection fraction; LAA, left atrial appendage; TEE, transesophageal echocardiography.
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abnormalities, endothelial dysfunction may contribute to the
hypercoagulability observed in patients with CHF [22]. Concordant
with these ﬁndings, a BNP level 4251.2 pg/mL, CHF (NYHA
classiﬁcation Z II), and systolic dysfunction (EF o40.2%) were
signiﬁcantly associated with the presence of LAA thrombus in the
present study.
Watanabe et al. [25] reported that elderly patients with an elevated
plasma BNP level have a greater incidence of systemic throm-
boembolism. LAA thrombus is reported to be associated with the
D-dimer level and thromboembolism in patients with NVAF [7–10].
In the present study, a positive association was found between
plasma BNP and D-Dimer levels, suggesting that plasma hypercoa-
gulability is closely associated with cardiac dysfunction. Addition-
ally, a negative association was found between the BNP level and
peak LAA velocity evaluated by using TEE. Peak LAA velocity
measured by using TEE has been proposed for assessing the degree
of blood stasis and risk of thromboembolism. These ﬁndings
indicate that the severity of CHF is associated with a hypercoagul-
able state possibly from blood stagnation in the LAA.
The results of the present study demonstrate that the BNP level
may be a useful surrogate marker for the presence of LAA thrombus.
In addition, BNP may be a quantitative and objective marker of risk
stratiﬁcation. In this study, a plasma BNP level 4251.2 pg/mL was an
independent predictor of LAA thrombus in patients with unanticoa-
gulated NVAF. Therefore, a plasma BNP level 4251.2 pg/mL may be
useful to differentiate between patients with and those without LAA
thrombus, and may provide better identiﬁcation of high-risk patients
with unanticoagulated NVAF. From these perspectives, measuring the
BNP level may help in the diagnosis of CHF and the detection of high-
risk patients by not only cardiologists but also general physicians.
Nevertheless, further prospective clinical studies are required to clarify
the impact of the cut-off levels of BNP determined in the present
study on the prognosis of patients with NVAF. The present ﬁndings
will contribute to the prompt detection of unanticoagulated NVAF
patients with high risk of thromboembolism.
4.1. Study limitations
This study has some limitations. The study was retrospective and
not double-blinded or randomized; therefore, it has the inherent
limitations of any single-center retrospective investigation. Although
there may have been some bias related to unmeasured factors, we
used multivariate analysis to carefully match patients in an effort to
eliminate bias. It should be noted that the incidence of LAA thrombus
Fig. 2. Distribution of CHADS2 scores in patients with and those without left atrial appendage thrombus. LAA, left atrial appendage.
Fig. 3. Correlations of the plasma brain natriuretic peptide level with the plasma D-dimer level and peak velocity of the left atrial appendage.
Y. Ochiumi et al. / Journal of Arrhythmia 31 (2015) 307–312310
is higher in the present study than in previous studies [1,26,27],
because patients with PT-INR Z2.0 were excluded. Additionally, good
control of warfarin may have affected the incidence of LAA thrombus.
Moreover, in this study, the prevalence of warfarin treatment (20.6%)
was lower, and patients admitted for thromboembolism were
excluded (including those with a history of systemic thromboembo-
lism). Some patients with paroxysmal AF were excluded in this study
because its onset could not be determined and its impact on the BNP
level was not known. Therefore, the plasma cut-off level of BNP in this
study differed from the cut-off levels determined in previous studies
[28,29].
Renal function has been recognized to have a close association
with the incidence of stroke [30]. In the present study, eGFR had a
strong inﬂuence on the presence of LAA thrombus. On multiple
logistic regression analysis including eGFR, the statistical signiﬁcance
of BNP disappeared. Originally, eGFR was not included as a risk factor
in the CHADS scoring system; therefore, eGFR was excluded from the
statistical analysis in the present study.
5. Conclusions
In patients with unanticoagulated NVAF, the BNP level may
help predict the incidence of LAA thrombus and may be used as a
surrogate marker of CHF in the CHADS2 scoring system. The BNP
level is clinically useful for the risk stratiﬁcation of systemic
thromboembolism in patients with unanticoagulated NVAF.
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